Cargando…

Monitoring Response to Transarterial Chemoembolization in Hepatocellular Carcinoma Using (18)F-Fluorothymidine PET

Accurate disease monitoring is essential after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) because of the potential for profound adverse events and large variations in survival outcome. Posttreatment changes on conventional imaging can confound determination of residual...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Rohini, Inglese, Marianna, Dubash, Suraiya, Lu, Haonan, Pinato, David J., Sanghera, Chandan, Patel, Neva, Chung, Anthony, Tait, Paul D., Mauri, Francesco, Crum, William R., Barwick, Tara D., Aboagye, Eric O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society of Nuclear Medicine 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679631/ https://www.ncbi.nlm.nih.gov/pubmed/32513905 http://dx.doi.org/10.2967/jnumed.119.240598

Ejemplares similares

[(18)F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer
por: Sharma, Rohini, et al.
Publicado: (2019)

Feasibility of [(18)F]fluoropivalate hybrid PET/MRI for imaging lower and higher grade glioma: a prospective first-in-patient pilot study
por: Islam, Shahriar, et al.
Publicado: (2023)

Spatial heterogeneity of radiolabeled choline positron emission tomography in tumors of patients with non-small cell lung cancer: first-in-patient evaluation of [(18)F]fluoromethyl-(1,2-(2)H(4))-choline
por: Dubash, Suraiya, et al.
Publicado: (2020)

A Subset of Non-Small Cell Lung Cancer Patients Treated with Pemetrexed Show (18)F-Fluorothymidine “Flare” on Positron Emission Tomography
por: Aravind, Preetha, et al.
Publicado: (2023)

Clinical translation of (18)F-fluoropivalate – a PET tracer for imaging short-chain fatty acid metabolism: safety, biodistribution, and dosimetry in fed and fasted healthy volunteers
por: Dubash, Suraiya R., et al.
Publicado: (2020)

Synthesis and evaluation of 3′-[(18)F]fluorothymidine-5′-squaryl as a bioisostere of 3′-[(18)F]fluorothymidine-5′-monophosphate
por: Brickute, D., et al.
Publicado: (2021)

Evaluation of (18)F-fluorothymidine positron emission tomography ([(18)F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer
por: Sharma, R., et al.
Publicado: (2016)

(18)F-fluorothymidine PET imaging in gliomas: an update
por: Nikaki, Alexandra, et al.
Publicado: (2017)

Evaluation of limited blood sampling population input approaches for kinetic quantification of [(18)F]fluorothymidine PET data
por: Contractor, Kaiyumars B, et al.
Publicado: (2012)

Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
por: Kloeckner, Roman, et al.
Publicado: (2015)

[(18)F]FET-βAG-TOCA: The Design, Evaluation and Clinical Translation of a Fluorinated Octreotide
por: Allott, Louis, et al.
Publicado: (2020)

Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma
por: Baur, Johannes, et al.
Publicado: (2016)

Repeated transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres vs. conventional transarterial chemoembolization for hepatocellular carcinoma
por: Fukushima, Taito, et al.
Publicado: (2021)

Comparison of the Treatment Response of Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma
por: Adel, Hatem, et al.
Publicado: (2023)

(18)F-fluorothymidine PET for predicting survival in patients with resectable pancreatic cancer
por: Wieder, Hinrich, et al.
Publicado: (2018)

Consideration of Metabolite Efflux in Radiolabelled Choline Kinetics
por: Li, Yunqing, et al.
Publicado: (2021)

Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma
por: Fateen, Waleed, et al.
Publicado: (2017)

Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?
por: Kotsifa, Evgenia, et al.
Publicado: (2022)

Rapid aneurysm growth after transarterial chemoembolization
por: Dansey, Kirsten, et al.
Publicado: (2015)

Ultraselective conventional transarterial chemoembolization: When and how?
por: Miyayama, Shiro
Publicado: (2019)

Radioembolization Followed by Transarterial Chemoembolization in Hepatocellular Carcinoma
por: Vardar, Baran U, et al.
Publicado: (2022)

Role of Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma
por: Zhong, Bin-Yan, et al.
Publicado: (2023)

In vivo imaging of cellular proliferation in renal cell carcinoma using 18F-fluorothymidine PET
por: Wong, Peter K., et al.
Publicado: (2014)

The Prognostic Value of (18)F-FDG PET/CT for Hepatocellular Carcinoma Treated with Transarterial Chemoembolization (TACE)
por: Ma, Wenhui, et al.
Publicado: (2014)

Sorafenib Combined with Transarterial Chemoembolization versus Transarterial Chemoembolization Alone for Advanced-Stage Hepatocellular Carcinoma: A Propensity Score Matching Study
por: Hu, Hao, et al.
Publicado: (2014)

Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula
por: Cai, Liang, et al.
Publicado: (2022)

A comparative study of efficacy and safety of transarterial chemoembolization with CalliSpheres and conventional transarterial chemoembolization in treating unresectable intrahepatic cholangiocarcinoma patients
por: Sun, Tao, et al.
Publicado: (2022)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma
por: Ren, Yanqiao, et al.
Publicado: (2022)

Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
por: Liu, Jun-Ning, et al.
Publicado: (2023)

Transarterial Chemoembolization Plus Sorafenib versus Transarterial Chemoembolization Alone for Advanced Hepatocellular Carcinoma: An Umbrella Review of Meta-Analyses and Systematic Reviews
por: Yan, Jingxin, et al.
Publicado: (2023)

Reliability of dynamic contrast-enhanced magnetic resonance imaging data in primary brain tumours: a comparison of Tofts and shutter speed models
por: Inglese, Marianna, et al.
Publicado: (2019)

The Current Practice of Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma
por: Shin, Sung Wook
Publicado: (2009)

Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
por: SHAO, WENBO, et al.
Publicado: (2014)

Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma
por: Nam, Hee Chul, et al.
Publicado: (2016)

Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review
por: Sacco, Rodolfo, et al.
Publicado: (2017)

Transarterial chemoembolization for hepatocellular carcinoma in Fontan surgery patient
por: Orlacchio, Antonio, et al.
Publicado: (2020)

Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma
por: Choi, Jonggi, et al.
Publicado: (2020)

Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Tsilimigras, Diamantis I., et al.
Publicado: (2020)

Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
por: Guo, Yusheng, et al.
Publicado: (2022)

Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE)
por: de Baere, Thierry, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_58rkrpk4l0jg1lc9ddg9h31mgp